インサイトの四半期報告

12-312025Q30000879169falseP3Y365365365367365365365xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesincy:segmentxbrli:pureincy:item00008791692025-01-012025-09-3000008791692025-10-2100008791692025-09-3000008791692024-12-310000879169us-gaap:ProductMember2025-07-012025-09-300000879169us-gaap:ProductMember2024-07-012024-09-300000879169us-gaap:ProductMember2025-01-012025-09-300000879169us-gaap:ProductMember2024-01-012024-09-300000879169us-gaap:RoyaltyMember2025-07-012025-09-300000879169us-gaap:RoyaltyMember2024-07-012024-09-300000879169us-gaap:RoyaltyMember2025-01-012025-09-300000879169us-gaap:RoyaltyMember2024-01-012024-09-300000879169incy:MilestoneAndContractRevenuesMember2025-07-012025-09-300000879169incy:MilestoneAndContractRevenuesMember2024-07-012024-09-300000879169incy:MilestoneAndContractRevenuesMember2025-01-012025-09-300000879169incy:MilestoneAndContractRevenuesMember2024-01-012024-09-3000008791692025-07-012025-09-3000008791692024-07-012024-09-3000008791692024-01-012024-09-300000879169us-gaap:CommonStockMember2024-12-310000879169us-gaap:AdditionalPaidInCapitalMember2024-12-310000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000879169us-gaap:RetainedEarningsMember2024-12-3100008791692025-01-012025-03-310000879169us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000879169us-gaap:RetainedEarningsMember2025-01-012025-03-310000879169us-gaap:CommonStockMember2025-03-310000879169us-gaap:AdditionalPaidInCapitalMember2025-03-310000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310000879169us-gaap:RetainedEarningsMember2025-03-3100008791692025-03-3100008791692025-04-012025-06-300000879169us-gaap:CommonStockMember2025-04-012025-06-300000879169us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300000879169us-gaap:RetainedEarningsMember2025-04-012025-06-300000879169us-gaap:CommonStockMember2025-06-300000879169us-gaap:AdditionalPaidInCapitalMember2025-06-300000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300000879169us-gaap:RetainedEarningsMember2025-06-3000008791692025-06-300000879169us-gaap:CommonStockMember2025-07-012025-09-300000879169us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300000879169us-gaap:RetainedEarningsMember2025-07-012025-09-300000879169us-gaap:CommonStockMember2025-09-300000879169us-gaap:AdditionalPaidInCapitalMember2025-09-300000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300000879169us-gaap:RetainedEarningsMember2025-09-300000879169us-gaap:CommonStockMember2023-12-310000879169us-gaap:AdditionalPaidInCapitalMember2023-12-310000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000879169us-gaap:RetainedEarningsMember2023-12-3100008791692023-12-3100008791692024-01-012024-03-310000879169us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000879169us-gaap:RetainedEarningsMember2024-01-012024-03-310000879169us-gaap:CommonStockMember2024-03-310000879169us-gaap:AdditionalPaidInCapitalMember2024-03-310000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000879169us-gaap:RetainedEarningsMember2024-03-3100008791692024-03-3100008791692024-04-012024-06-300000879169us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000879169us-gaap:CommonStockMember2024-04-012024-06-300000879169us-gaap:RetainedEarningsMember2024-04-012024-06-300000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000879169us-gaap:CommonStockMember2024-06-300000879169us-gaap:AdditionalPaidInCapitalMember2024-06-300000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000879169us-gaap:RetainedEarningsMember2024-06-3000008791692024-06-300000879169us-gaap:CommonStockMember2024-07-012024-09-300000879169us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000879169us-gaap:RetainedEarningsMember2024-07-012024-09-300000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000879169us-gaap:CommonStockMember2024-09-300000879169us-gaap:AdditionalPaidInCapitalMember2024-09-300000879169us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000879169us-gaap:RetainedEarningsMember2024-09-3000008791692024-09-300000879169incy:JAKAFIMember2025-07-012025-09-300000879169incy:JAKAFIMember2024-07-012024-09-300000879169incy:JAKAFIMember2025-01-012025-09-300000879169incy:JAKAFIMember2024-01-012024-09-300000879169incy:OPZELURAMember2025-07-012025-09-300000879169incy:OPZELURAMember2024-07-012024-09-300000879169incy:OPZELURAMember2025-01-012025-09-300000879169incy:OPZELURAMember2024-01-012024-09-300000879169incy:ICLUSIGMember2025-07-012025-09-300000879169incy:ICLUSIGMember2024-07-012024-09-300000879169incy:ICLUSIGMember2025-01-012025-09-300000879169incy:ICLUSIGMember2024-01-012024-09-300000879169incy:PEMAZYREMember2025-07-012025-09-300000879169incy:PEMAZYREMember2024-07-012024-09-300000879169incy:PEMAZYREMember2025-01-012025-09-300000879169incy:PEMAZYREMember2024-01-012024-09-300000879169incy:MINJUVIMONJUVIMember2025-07-012025-09-300000879169incy:MINJUVIMONJUVIMember2024-07-012024-09-300000879169incy:MINJUVIMONJUVIMember2025-01-012025-09-300000879169incy:MINJUVIMONJUVIMember2024-01-012024-09-300000879169incy:NIKTIMVOMember2025-07-012025-09-300000879169incy:NIKTIMVOMember2024-07-012024-09-300000879169incy:NIKTIMVOMember2025-01-012025-09-300000879169incy:NIKTIMVOMember2024-01-012024-09-300000879169incy:ZYNYZMember2025-07-012025-09-300000879169incy:ZYNYZMember2024-07-012024-09-300000879169incy:ZYNYZMember2025-01-012025-09-300000879169incy:ZYNYZMember2024-01-012024-09-300000879169incy:JAKAVIRoyaltyRevenuesMember2025-07-012025-09-300000879169incy:JAKAVIRoyaltyRevenuesMember2024-07-012024-09-300000879169incy:JAKAVIRoyaltyRevenuesMember2025-01-012025-09-300000879169incy:JAKAVIRoyaltyRevenuesMember2024-01-012024-09-300000879169incy:OLUMIANTRoyaltyRevenuesMember2025-07-012025-09-300000879169incy:OLUMIANTRoyaltyRevenuesMember2024-07-012024-09-300000879169incy:OLUMIANTRoyaltyRevenuesMember2025-01-012025-09-300000879169incy:OLUMIANTRoyaltyRevenuesMember2024-01-012024-09-300000879169incy:TABRECTARoyaltyRevenuesMember2025-07-012025-09-300000879169incy:TABRECTARoyaltyRevenuesMember2024-07-012024-09-300000879169incy:TABRECTARoyaltyRevenuesMember2025-01-012025-09-300000879169incy:TABRECTARoyaltyRevenuesMember2024-01-012024-09-300000879169incy:OtherProductRoyaltyRevenuesMember2025-07-012025-09-300000879169incy:OtherProductRoyaltyRevenuesMember2024-07-012024-09-300000879169incy:OtherProductRoyaltyRevenuesMember2025-01-012025-09-300000879169incy:OtherProductRoyaltyRevenuesMember2024-01-012024-09-300000879169incy:CorporateAndGovernmentDebtSecuritiesMember2025-09-300000879169incy:CorporateAndGovernmentDebtSecuritiesMember2024-12-310000879169us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-09-300000879169us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-09-300000879169us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-09-300000879169us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-09-300000879169us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310000879169us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310000879169us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310000879169us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000879169us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2024-12-310000879169us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-09-300000879169us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-09-300000879169incy:AriadPharmaceuticalsMemberus-gaap:LiabilityMember2016-06-012016-06-010000879169incy:AriadPharmaceuticalsMemberus-gaap:LiabilityMemberus-gaap:MeasurementInputDiscountRateMember2016-06-010000879169incy:AriadPharmaceuticalsMemberus-gaap:LiabilityMemberus-gaap:MeasurementInputDiscountRateMember2024-12-310000879169incy:AriadPharmaceuticalsMemberus-gaap:LiabilityMemberus-gaap:MeasurementInputDiscountRateMember2025-09-300000879169incy:AriadPharmaceuticalsMember2025-01-012025-09-300000879169incy:AriadPharmaceuticalsMember2024-01-012024-12-310000879169incy:NovartisAndLillyMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-09-300000879169incy:NovartisAndLillyMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310000879169incy:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300000879169incy:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300000879169incy:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-300000879169incy:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300000879169incy:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300000879169incy:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300000879169incy:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-300000879169incy:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300000879169incy:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300000879169incy:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300000879169incy:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-300000879169incy:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300000879169incy:CustomerDMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300000879169incy:CustomerDMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300000879169incy:CustomerDMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-300000879169incy:CustomerDMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300000879169incy:CustomerEMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300000879169incy:CustomerEMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300000879169incy:CustomerEMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-300000879169incy:CustomerEMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300000879169incy:CustomerFMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-07-012025-09-300000879169incy:CustomerFMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-07-012024-09-300000879169incy:CustomerFMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2025-01-012025-09-300000879169incy:CustomerFMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300000879169incy:CustomerABCDEAndFMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-09-300000879169incy:CustomerABCDEAndFMemberus-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310000879169incy:MorphoSysAGMember2024-02-052024-02-050000879169incy:XencorMember2025-01-012025-03-310000879169incy:RegulatoryMilestoneMemberincy:XencorMember2025-06-012025-06-300000879169incy:DevelopmentAndRegulatoryMilestonesMemberincy:XencorMembersrt:MaximumMember2025-09-300000879169incy:CommercializationMilestonesMemberincy:XencorMembersrt:MaximumMember2025-09-300000879169incy:CommercializationMilestonesMemberincy:XencorMembersrt:MaximumMember2024-02-052024-02-050000879169srt:MaximumMemberincy:XencorMember2024-02-050000879169srt:MinimumMemberincy:XencorMember2024-02-050000879169incy:EscientPharmaceuticalsMember2024-05-302024-05-300000879169incy:EscientPharmaceuticalsMember2024-04-012024-06-300000879169incy:InProcessResearchAndDevelopmentINCB000262Memberincy:EscientPharmaceuticalsMember2024-05-302024-05-300000879169incy:InProcessResearchAndDevelopmentINCB000547Memberincy:EscientPharmaceuticalsMember2024-05-302024-05-300000879169incy:EscientPharmaceuticalsMember2025-01-012025-09-300000879169srt:MinimumMember2025-01-012025-09-300000879169srt:MaximumMember2025-01-012025-09-300000879169incy:DevelopmentMilestonesMemberincy:NovartisMembersrt:MaximumMember2009-11-012009-11-300000879169incy:RegulatoryMilestonesMemberincy:NovartisMembersrt:MaximumMember2009-11-012009-11-300000879169incy:CommercializationMilestonesMemberincy:NovartisMembersrt:MaximumMember2009-11-012009-11-300000879169incy:DevelopmentAndRegulatoryMilestonesMemberincy:GVHDMemberincy:NovartisMembersrt:MaximumMember2009-11-012009-11-300000879169incy:DevelopmentMilestonesMemberincy:NovartisMember2009-11-012025-09-300000879169incy:RegulatoryMilestonesMemberincy:NovartisMember2009-11-012025-09-300000879169incy:CommercializationMilestonesMemberincy:NovartisMember2009-11-012025-09-300000879169incy:JAKAFIMemberincy:NovartisMember2025-03-310000879169incy:JAKAFIMemberincy:NovartisMember2025-05-112025-05-110000879169incy:JAKAFIMemberincy:NovartisMember2025-01-012025-03-310000879169incy:JAKAFIMemberincy:NovartisMember2025-01-012025-09-300000879169incy:JAKAFIMembercountry:USincy:NovartisMember2025-07-012025-09-300000879169incy:JAKAFIMembercountry:USincy:NovartisMember2025-01-012025-09-300000879169incy:JAKAFIMembercountry:USincy:NovartisMember2024-07-012024-09-300000879169incy:JAKAFIMembercountry:USincy:NovartisMember2024-01-012024-09-300000879169incy:JAKAFIMembercountry:USincy:NovartisMember2025-09-300000879169incy:JAKAFIMembercountry:USincy:NovartisMember2024-12-310000879169incy:JakaviMemberincy:NovartisMembersrt:MinimumMember2025-01-012025-09-300000879169incy:JakaviMemberincy:NovartisMembersrt:MaximumMember2025-01-012025-09-300000879169incy:JAKAVIMemberincy:NovartisMember2025-07-012025-09-300000879169incy:JAKAVIMemberincy:NovartisMember2025-01-012025-09-300000879169incy:JAKAVIMemberincy:NovartisMember2024-07-012024-09-300000879169incy:JAKAVIMemberincy:NovartisMember2024-01-012024-09-300000879169incy:TABRECTAMemberincy:NovartisMember2025-07-012025-09-300000879169incy:TABRECTAMemberincy:NovartisMember2025-01-012025-09-300000879169incy:TABRECTAMemberincy:NovartisMember2024-07-012024-09-300000879169incy:TABRECTAMemberincy:NovartisMember2024-01-012024-09-300000879169incy:DevelopmentMilestonesMemberincy:EliLillyMembersrt:MaximumMember2009-12-012009-12-310000879169incy:RegulatoryMilestonesMemberincy:EliLillyMembersrt:MaximumMember2009-12-012009-12-310000879169incy:CommercializationMilestonesMemberincy:EliLillyMembersrt:MaximumMember2009-12-012009-12-310000879169incy:DevelopmentMilestonesMemberincy:EliLillyMember2009-12-012025-09-300000879169incy:RegulatoryMilestonesMemberincy:EliLillyMember2009-12-012025-09-300000879169incy:CommercializationMilestonesMemberincy:EliLillyMember2009-12-012025-09-300000879169incy:EliLillyMemberus-gaap:SubsequentEventMember2025-10-012025-10-310000879169incy:OLUMIANTMemberincy:EliLillyMember2025-07-012025-09-300000879169incy:OLUMIANTMemberincy:EliLillyMember2025-01-012025-09-300000879169incy:OLUMIANTMemberincy:EliLillyMember2024-07-012024-09-300000879169incy:OLUMIANTMemberincy:EliLillyMember2024-01-012024-09-300000879169incy:AgenusMember2024-07-012024-09-300000879169incy:AgenusMember2024-01-012024-09-300000879169incy:MerusMember2016-12-012016-12-310000879169incy:MerusMember2024-07-012024-09-300000879169incy:MerusMember2024-01-012024-09-300000879169incy:DevelopmentalAndRegulatoryMilestonesMemberincy:MacroGenicsMember2017-10-012025-09-300000879169incy:DevelopmentAndRegulatoryMilestonesMemberincy:MacroGenicsMembersrt:MaximumMember2025-09-300000879169incy:CommercializationMilestonesMemberincy:MacroGenicsMembersrt:MaximumMember2025-09-300000879169srt:MinimumMemberincy:MacroGenicsMember2025-01-012025-09-300000879169srt:MaximumMemberincy:MacroGenicsMember2025-01-012025-09-300000879169incy:MorphoSysAGMemberincy:IncyteMember2024-02-052024-02-050000879169incy:MorphoSysAGMemberincy:MorphoSysAGMember2024-02-052024-02-050000879169incy:MorphoSysAGMember2024-01-012024-09-300000879169incy:MorphoSysAGMember2024-01-012024-02-050000879169country:USincy:SyndaxPharmaceuticalsIncMemberincy:IncyteMember2021-09-012021-09-300000879169country:USincy:SyndaxPharmaceuticalsIncMemberincy:SyndaxPharmaceuticalsIncMember2021-09-012021-09-300000879169incy:RegulatoryMilestoneMemberincy:SyndaxPharmaceuticalsIncMember2024-08-012024-08-310000879169incy:SyndaxPharmaceuticalsIncMember2021-09-012025-09-300000879169incy:DevelopmentAndRegulatoryMilestonesMemberincy:SyndaxPharmaceuticalsIncMembersrt:MaximumMember2025-09-300000879169incy:CommercializationMilestonesMemberincy:SyndaxPharmaceuticalsIncMembersrt:MaximumMember2025-09-300000879169incy:InvestmentInSyndaxMember2025-09-300000879169incy:InvestmentInSyndaxMember2024-12-310000879169incy:InvestmentInSyndaxMember2025-07-012025-09-300000879169incy:InvestmentInSyndaxMember2025-01-012025-09-300000879169incy:InvestmentInSyndaxMember2024-07-012024-09-300000879169incy:InvestmentInSyndaxMember2024-01-012024-09-300000879169incy:SyndaxPharmaceuticalsIncMember2025-07-012025-09-300000879169incy:SyndaxPharmaceuticalsIncMember2025-01-012025-09-300000879169incy:SyndaxPharmaceuticalsIncMemberincy:IncyteMember2025-01-012025-09-300000879169incy:SyndaxPharmaceuticalsIncMemberincy:IncyteMember2025-07-012025-09-300000879169incy:SyndaxPharmaceuticalsIncMember2024-07-012024-09-300000879169incy:SyndaxPharmaceuticalsIncMember2024-01-012024-09-300000879169incy:SyndaxPharmaceuticalsIncMemberincy:IncyteMember2024-07-012024-09-300000879169incy:SyndaxPharmaceuticalsIncMemberincy:IncyteMember2024-01-012024-09-300000879169incy:SyndaxPharmaceuticalsIncMember2025-09-300000879169incy:SyndaxPharmaceuticalsIncMember2024-12-310000879169incy:CMSHLMember2024-03-012024-03-310000879169us-gaap:OfficeEquipmentMember2025-09-300000879169us-gaap:OfficeEquipmentMember2024-12-310000879169us-gaap:EquipmentMember2025-09-300000879169us-gaap:EquipmentMember2024-12-310000879169us-gaap:ComputerEquipmentMember2025-09-300000879169us-gaap:ComputerEquipmentMember2024-12-310000879169us-gaap:LandMember2025-09-300000879169us-gaap:LandMember2024-12-310000879169incy:BuildingAndLeaseholdImprovementsMember2025-09-300000879169incy:BuildingAndLeaseholdImprovementsMember2024-12-310000879169incy:OperatingLeaseRightOfUseAssetsMember2025-09-300000879169incy:OperatingLeaseRightOfUseAssetsMember2024-12-310000879169us-gaap:ConstructionInProgressMember2025-09-300000879169us-gaap:ConstructionInProgressMember2024-12-3100008791692024-05-012024-05-310000879169us-gaap:LandMember2024-01-012024-12-310000879169incy:BuildingAndLeaseholdImprovementsMember2024-01-012024-12-310000879169incy:DowntownWilmingtonMemberus-gaap:ConstructionInProgressMember2025-09-300000879169incy:StockIncentivePlan2010Member2025-05-310000879169incy:StockIncentivePlan2010Member2025-06-300000879169incy:A2024InducementPlanMember2025-09-300000879169incy:BoardOfDirectorsApprovedShareRepurchaseProgramMember2024-05-130000879169incy:DutchAuctionTenderOfferMember2024-05-140000879169srt:MaximumMemberincy:DutchAuctionTenderOfferMember2024-05-130000879169srt:MinimumMemberincy:DutchAuctionTenderOfferMember2024-05-130000879169incy:DutchAuctionTenderOfferMember2024-06-132024-06-130000879169incy:BakerEntitiesShareRepurchaseProgramMember2024-05-120000879169incy:IncyteMemberincy:BakerEntitiesMember2024-05-090000879169incy:BakerEntitiesShareRepurchaseProgramMember2024-06-262024-06-2600008791692024-06-012024-06-300000879169us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000879169us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-12-310000879169us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000879169us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-09-300000879169us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-01-012025-09-300000879169us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-09-300000879169us-gaap:AccumulatedTranslationAdjustmentMember2025-09-300000879169us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-09-300000879169us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-09-300000879169us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000879169us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000879169us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000879169us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000879169us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-09-300000879169us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300000879169us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000879169us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300000879169us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000879169us-gaap:ResearchAndDevelopmentExpenseMember2025-07-012025-09-300000879169us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-09-300000879169us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000879169us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000879169us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-07-012025-09-300000879169us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-09-300000879169us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300000879169us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000879169us-gaap:CostOfSalesMember2025-07-012025-09-300000879169us-gaap:CostOfSalesMember2025-01-012025-09-300000879169us-gaap:CostOfSalesMember2024-07-012024-09-300000879169us-gaap:CostOfSalesMember2024-01-012024-09-300000879169incy:EscientPharmaceuticalsMember2024-01-012024-09-300000879169us-gaap:EmployeeStockOptionMember2025-07-012025-09-300000879169us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000879169us-gaap:EmployeeStockOptionMember2025-01-012025-09-300000879169us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000879169us-gaap:EmployeeStockMember2025-07-012025-09-300000879169us-gaap:EmployeeStockMember2024-07-012024-09-300000879169us-gaap:EmployeeStockMember2025-01-012025-09-300000879169us-gaap:EmployeeStockMember2024-01-012024-09-300000879169us-gaap:EmployeeStockOptionMember2024-12-310000879169us-gaap:EmployeeStockOptionMember2025-09-300000879169us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-01-012025-09-300000879169us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-01-012025-09-300000879169us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300000879169us-gaap:PerformanceSharesMember2025-01-012025-09-300000879169srt:MinimumMemberus-gaap:PerformanceSharesMember2025-01-012025-09-300000879169srt:MaximumMemberus-gaap:PerformanceSharesMember2025-01-012025-09-300000879169us-gaap:PerformanceSharesMember2025-07-012025-09-300000879169us-gaap:PerformanceSharesMember2024-07-012024-09-300000879169us-gaap:PerformanceSharesMember2024-01-012024-09-3000008791692025-01-012025-05-3100008791692025-06-012025-06-300000879169incy:StockIncentivePlan2010Member2025-01-012025-09-300000879169incy:A2024InducementPlanMember2025-01-012025-09-300000879169us-gaap:RestrictedStockUnitsRSUMember2025-09-300000879169us-gaap:PerformanceSharesMember2025-09-300000879169us-gaap:StockCompensationPlanMember2025-07-012025-09-300000879169us-gaap:StockCompensationPlanMember2024-07-012024-09-300000879169us-gaap:StockCompensationPlanMember2025-01-012025-09-300000879169us-gaap:StockCompensationPlanMember2024-01-012024-09-300000879169us-gaap:RevolvingCreditFacilityMember2021-08-310000879169us-gaap:RevolvingCreditFacilityMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2021-08-012021-08-310000879169us-gaap:RevolvingCreditFacilityMember2025-09-300000879169us-gaap:RevolvingCreditFacilityMember2024-12-310000879169incy:JAKAFIMemberincy:USCentersForMedicareAndMedicaidServicesMemberincy:AccruedAndOtherCurrentLiabilitiesMember2025-09-300000879169incy:JAKAFIMemberincy:USCentersForMedicareAndMedicaidServicesMember2025-07-012025-09-300000879169us-gaap:ProductMemberincy:ReportableSegmentMember2025-07-012025-09-300000879169us-gaap:ProductMemberincy:ReportableSegmentMember2024-07-012024-09-300000879169us-gaap:ProductMemberincy:ReportableSegmentMember2025-01-012025-09-300000879169us-gaap:ProductMemberincy:ReportableSegmentMember2024-01-012024-09-300000879169us-gaap:RoyaltyMemberincy:ReportableSegmentMember2025-07-012025-09-300000879169us-gaap:RoyaltyMemberincy:ReportableSegmentMember2024-07-012024-09-300000879169us-gaap:RoyaltyMemberincy:ReportableSegmentMember2025-01-012025-09-300000879169us-gaap:RoyaltyMemberincy:ReportableSegmentMember2024-01-012024-09-300000879169incy:MilestoneAndContractRevenuesMemberincy:ReportableSegmentMember2025-07-012025-09-300000879169incy:MilestoneAndContractRevenuesMemberincy:ReportableSegmentMember2024-07-012024-09-300000879169incy:MilestoneAndContractRevenuesMemberincy:ReportableSegmentMember2025-01-012025-09-300000879169incy:MilestoneAndContractRevenuesMemberincy:ReportableSegmentMember2024-01-012024-09-300000879169incy:ReportableSegmentMember2025-07-012025-09-300000879169incy:ReportableSegmentMember2024-07-012024-09-300000879169incy:ReportableSegmentMember2025-01-012025-09-300000879169incy:ReportableSegmentMember2024-01-012024-09-300000879169country:US2025-07-012025-09-300000879169country:US2024-07-012024-09-300000879169country:US2025-01-012025-09-300000879169country:US2024-01-012024-09-300000879169srt:EuropeMember2025-07-012025-09-300000879169srt:EuropeMember2024-07-012024-09-300000879169srt:EuropeMember2025-01-012025-09-300000879169srt:EuropeMember2024-01-012024-09-300000879169incy:OtherCountriesMember2025-07-012025-09-300000879169incy:OtherCountriesMember2024-07-012024-09-300000879169incy:OtherCountriesMember2025-01-012025-09-300000879169incy:OtherCountriesMember2024-01-012024-09-300000879169country:US2025-09-300000879169country:US2024-12-310000879169country:CH2025-09-300000879169country:CH2024-12-310000879169incy:OtherCountriesMember2025-09-300000879169incy:OtherCountriesMember2024-12-310000879169incy:HerveHoppenotMember2025-07-012025-09-300000879169incy:HerveHoppenotMember2025-09-300000879169incy:StevenSteinMember2025-07-012025-09-300000879169incy:StevenSteinMember2025-09-300000879169incy:LeeHeesonMember2025-07-012025-09-300000879169incy:LeeHeesonMember2025-09-300000879169incy:ThomasTrayMember2025-07-012025-09-300000879169incy:ThomasTrayMember2025-09-300000879169incy:PatrickMayesMember2025-07-012025-09-300000879169incy:PatrickMayesMember2025-09-300000879169incy:MichaelMorrisseyMember2025-07-012025-09-300000879169incy:MichaelMorrisseyMember2025-09-300000879169incy:MohamedIssaMember2025-07-012025-09-300000879169incy:MohamedIssaMember2025-09-30


x			1934年米国証券取引所法（securities exchange act of 1934）第13条または第15条(d)に基づく四半期報告書


デラウェア			94-3136539
(法人または組織の州またはその他の管轄区域)			(IRS EmployerIdentification No.)

1801 オーガスティン・カットオフウィルミントン, de 19803			19803
(主要経営陣の住所)			(Zip Code)


Large accelerated filer ☒			Accelerated filer o

Non-accelerated filer o			Smaller reporting company o

			Emerging growth company o


パート I：財務情報		3

項目1.	財務諸表	3

	要約連結貸借対照表	3

	要約連結損益計算書	4

	要約連結包括利益計算書 (損失)	5

	要約連結株主資本等変動計算書	6

	要約連結キャッシュ・フロー計算書	8

	要約連結財務諸表注記	9

項目2.	財政状態および経営成績に関する経営陣の検討および分析	32

	将来の見通しに関する記述	32

	要約リスク要因	35

項目3.	市場リスクに関する定量的・定性的開示	53

項目4.	管理と手続き	54

パート II: その他の情報

項目1.	法的手続き	54

項目1A	リスク要因	54

項目5.	その他の情報	82

項目6.	展示品	84

	署名	85


	September 30,2025		December 31,2024*
	(未監査)
資産
流動資産:
現金および現金同等物	$	2,455,006	$	1,687,829
売却可能有価証券（2025年9月30日および2024年12月31日現在の償却原価はそれぞれ473,126ドルおよび469,917ドル、2025年9月30日および2024年12月31日現在の貸倒引当金は0ドル)	474,814		470,263
売掛金	895,890		853,154
棚卸資産	83,447		58,872
前払費用およびその他の流動資産	368,732		168,912
流動資産合計	4,277,889		3,239,030

制限付き現金	1,843		1,622
Long term equity investments	21,870		18,814
棚卸資産	366,510		348,327
有形固定資産(純額)	798,634		763,411
ファイナンス・リース使用権資産（純額	28,155		30,803
その他の無形固定資産(純額)	119,421		113,803
営業権	155,593		155,593
繰延税金資産	528,138		762,071
その他の資産（純額	32,303		10,848
資産合計	$	6,330,356	$	5,444,322

LIABILITIES AND STOCKHOLDERS’ EQUITY
現在の負債:
買掛金	$	171,925	$	197,465
Accrued compensation	168,250		188,677
未払費用およびその他の流動負債	948,439		1,212,048
Finance lease liabilities	4,491		4,419
Acquisition-related contingent consideration	45,624		39,238
流動負債合計	1,338,729		1,641,847

Acquisition-related contingent consideration	138,376		153,762
Finance lease liabilities	30,881		33,542
その他の負債	171,176		167,543
負債合計	1,679,162		1,996,694

コミットメントおよび偶発事象（注記17)

株主資本の部:
優先株式、額面0.001ドル、授権株式数5,000,000株、発行済株式なし	—		—
普通株式、額面0.001ドル、授権株式数400,000,000株、2025年9月30日および2024年12月31日現在の発行済株式数はそれぞれ196,130,993株および193,434,305株	196		193
資本準備金	4,721,953		4,533,437
その他の包括利益（損失）累計額)	14,555		(13,121)
累積赤字	(85,510)		(1,072,881)
株主資本合計	4,651,194		3,447,628
負債および株主資本合計	$	6,330,356	$	5,444,322


	Three Months EndedSeptember 30,				Nine Months EndedSeptember 30,
	2025		2024		2025		2024
売上高:
Product revenues, net	$	1,149,856	$	962,992	$	3,131,544	$	2,599,481
Product royalty revenues	171,124		156,879		452,863		420,038
Milestone and contract revenues	45,000		18,000		50,000		43,000
収益合計	1,365,980		1,137,871		3,634,407		3,062,519

Costs, expenses and other:
製品売上原価（定義済みの無形資産償却費を含む)	99,001		85,993		250,955		223,583
Contract dispute settlement	—		—		(242,251)		—
研究開発費	506,584		573,174		1,438,780		2,140,814
販売費及び一般管理費	329,081		309,209		985,794		915,447
(買収に関連する偶発対価の公正価値の変動に伴う利益（損失	(12,204)		23,410		22,129		23,847
(共同研究契約にもとづく利益）および損失分配	—		—		—		(1,025)
コスト、費用およびその他の合計	922,462		991,786		2,455,407		3,302,666

営業利益(損失)	443,518		146,085		1,179,000		(240,147)
受取利息	26,781		19,266		74,846		107,512
支払利息	(592)		(774)		(1,846)		(1,861)
持分法による投資利益（損失	8,558		(12,982)		3,064		126,206
その他（純額	4,043		4,929		19,446		11,196
税金等調整前利益	482,308		156,524		1,274,510		2,906
法人税等の支払額	58,139		50,068		287,139		171,503
Net income (loss)	$	424,169	$	106,456	$	987,371	$	(168,597)

1株当たり当期純利益（損失）:
基本	$	2.17	$	0.55	$	5.08	$	(0.80)
希薄化後	$	2.11	$	0.54	$	4.95	$	(0.80)

1株当たり当期純利益（損失）の計算に用いられた株式数:
基本	195,670		192,629		194,459		211,763
希薄化後	201,429		195,838		199,405		211,763


	CommonStock		AdditionalPaid-in Capital		Accumulated OtherComprehensive (Loss) Income		累積赤字		TotalStockholders’Equity
2025年1月1日時点の残高	$	193	$	4,533,437	$	(13,121)	$	(1,072,881)	$	3,447,628
ストック・オプションの行使および従業員譲渡制限付株式ユニットの決済に伴う普通株式363,987株の発行（税控除後	—		(6,215)		—		—		(6,215)
役務提供に対する普通株式1,208株の発行	—		82		—		—		82
株式報酬	—		60,982		—		—		60,982
Other comprehensive income	—		—		6,883		—		6,883
純利益	—		—		—		158,203		158,203
2025年3月31日現在残高	$	193	$	4,588,286	$	(6,238)	$	(914,678)	$	3,667,563
ストック・オプションの行使、従業員の譲渡制限付ストック・ユニットおよびパフォーマンス・シェアの決済による普通株式64,400株（税控除後）、およびesppによる普通株式261,762株の発行。	1		13,972		—		—		13,973
役務提供に対する普通株式1,220株の発行	—		82		—		—		82
株式報酬	—		64,609		—		—		64,609
Other comprehensive income	—		—		19,677		—		19,677
純利益	—		—		—		404,999		404,999
2025年6月30日現在の残高	$	194	$	4,666,949	$	13,439	$	(509,679)	$	4,170,903
ストック・オプションの行使および従業員譲渡制限付株式ユニットの決済による普通株式2,011,476株の発行（税控除後	2		(6,676)		—		—		(6,674)
役務提供に対する普通株式962株の発行	—		82		—		—		82
株式報酬	—		61,598		—		—		61,598
Other comprehensive income	—		—		1,116		—		1,116
純利益	—		—		—		424,169		424,169
2025年9月30日現在残高	$	196	$	4,721,953	$	14,555	$	(85,510)	$	4,651,194